NO306728B1 - Fremgangsmåte for fremstilling av en human rekombinant TNF inhibitor og nukleinsyre - Google Patents

Fremgangsmåte for fremstilling av en human rekombinant TNF inhibitor og nukleinsyre

Info

Publication number
NO306728B1
NO306728B1 NO903192A NO903192A NO306728B1 NO 306728 B1 NO306728 B1 NO 306728B1 NO 903192 A NO903192 A NO 903192A NO 903192 A NO903192 A NO 903192A NO 306728 B1 NO306728 B1 NO 306728B1
Authority
NO
Norway
Prior art keywords
tnf
tnf inhibitor
inhibitor
40kda
preparation
Prior art date
Application number
NO903192A
Other languages
English (en)
Other versions
NO306728B3 (no
NO903192L (no
NO903192D0 (no
Inventor
Michael T Brewer
Karin K Hale
Michael W King
Tadahiko Kohno
Charles Squires
Robert C Thompson
Rebecca W Vanderslice
James Vannice
Original Assignee
Synergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27409520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO306728(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synergen Inc filed Critical Synergen Inc
Publication of NO903192D0 publication Critical patent/NO903192D0/no
Publication of NO903192L publication Critical patent/NO903192L/no
Publication of NO306728B1 publication Critical patent/NO306728B1/no
Publication of NO306728B3 publication Critical patent/NO306728B3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO903192A 1989-07-18 1990-07-17 Fremgangsmåte for fremstilling av en human rekombinant TNF inhibitor og nukleinsyre NO306728B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38108089A 1989-07-18 1989-07-18
US45032989A 1989-12-11 1989-12-11
US47966190A 1990-02-07 1990-02-07

Publications (4)

Publication Number Publication Date
NO903192D0 NO903192D0 (no) 1990-07-17
NO903192L NO903192L (no) 1991-01-21
NO306728B1 true NO306728B1 (no) 1999-12-13
NO306728B3 NO306728B3 (no) 2003-02-17

Family

ID=27409520

Family Applications (1)

Application Number Title Priority Date Filing Date
NO903192A NO306728B1 (no) 1989-07-18 1990-07-17 Fremgangsmåte for fremstilling av en human rekombinant TNF inhibitor og nukleinsyre

Country Status (21)

Country Link
US (1) US6541620B1 (no)
EP (2) EP0790306A3 (no)
JP (1) JPH03163099A (no)
KR (1) KR100230156B1 (no)
AT (1) ATE162801T1 (no)
AU (1) AU647397B2 (no)
CA (1) CA2021369A1 (no)
DE (1) DE69031997T2 (no)
DK (1) DK0422339T3 (no)
ES (1) ES2116970T3 (no)
FI (1) FI114398B (no)
GR (1) GR3026416T3 (no)
HK (1) HK1014539A1 (no)
IE (2) IE990595A1 (no)
IL (2) IL95031A (no)
NO (1) NO306728B1 (no)
NZ (1) NZ234499A (no)
PL (1) PL168844B1 (no)
PT (1) PT94754B (no)
SG (1) SG55131A1 (no)
TW (1) TW206234B (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811261A (en) * 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
DE59010941D1 (de) * 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6232446B1 (en) 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
US6262239B1 (en) 1989-05-18 2001-07-17 Yeda Research And Development Co., Ltd. TNF receptor-specific antibodies
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
EP0480389A1 (de) * 1990-10-12 1992-04-15 Hoechst Aktiengesellschaft Inhibitoren für die Bildung von Tumor Nekrose Faktor, Verfahren zu deren Herstellung und deren Verwendung
GB9027917D0 (en) 1990-12-21 1991-02-13 Ici Plc Expression systems
JP2864434B2 (ja) * 1991-01-18 1999-03-03 サイナーゲン，インコーポレーテッド 腫瘍壊死因子媒介疾患の治療方法
NZ251820A (en) * 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
PT639079E (pt) * 1992-04-30 2000-04-28 Amgen Inc Composicao para tratamento de doencas mediadas por interleuquina-1 e factor de necrose tumoral
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
BR9707325A (pt) 1996-02-09 1999-04-13 Amgen Inc Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JP2001513754A (ja) 1996-12-06 2001-09-04 アムジェン インコーポレイテッド Ｔｎｆ媒介疾患を処置するためのｔｎｆ結合タンパク質を使用する組み合わせ治療
CA2273852C (en) 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
AU744997B2 (en) * 1997-09-05 2002-03-07 Glaxo Group Limited 2,3-diaryl-pyrazolo(1,5-B)pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2401683A1 (en) 2000-03-02 2001-09-07 Xencor Design and discovery of protein based tnf-.alpha. variants for the treatment of tnf-.alpha. related disorders
AR030554A1 (es) 2000-03-16 2003-08-27 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
US7879448B2 (en) * 2000-07-11 2011-02-01 Guardian Industires Corp. Coated article with low-E coating including IR reflecting layer(s) and corresponding method
US7153669B2 (en) 2000-09-05 2006-12-26 Amgen Inc. Nucleic acids encoding MK61 receptors
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
YU103003A (sh) 2001-06-26 2006-05-25 Abgenix Inc. Antitela za opgl
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
JP2006517191A (ja) 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド 共刺激因子を用いた併用療法
AU2004287431B2 (en) 2003-10-27 2010-03-11 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
CA2629323A1 (en) * 2005-11-10 2007-05-24 The University Of North Carolina At Chapel Hill Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
US7785834B2 (en) * 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US20090264353A1 (en) * 2007-10-19 2009-10-22 Santaris Pharma A/S Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
US8293101B2 (en) 2009-03-13 2012-10-23 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
HUE046670T2 (hu) 2010-01-15 2020-03-30 Kirin Amgen Inc Anti IL-17RA ellenanyag kiszerelés és terápiás rendek pikkelysömör kezelésére
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
AU2015241373B2 (en) 2014-03-31 2020-11-05 Amgen K-A, Inc. Methods of treating nail and scalp psoriasis

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IN150740B (no) 1978-11-24 1982-12-04 Hoffmann La Roche
US4560649A (en) 1981-10-15 1985-12-24 Cornell Research Foundation Assaying for hLH or hCG with immobilized hormone receptors
JPH0751511B2 (ja) 1982-03-15 1995-06-05 味の素株式会社 インターロイキン２を含有してなる癌治療剤
US4587046A (en) 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4966888A (en) 1985-07-08 1990-10-30 Cornell Research Foundation, Inc. hCG-hLH receptor and hCG-hLH receptor-hCG complex as antigens, antibodies thereto and contraceptive vaccine
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4578335A (en) 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
CA1339269C (en) 1984-05-21 1997-08-12 Douglas P. Cerretti Purification of and cloning of the gene for interleukin-2 receptor
US4675285A (en) 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
CA1283046C (en) 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
IN165717B (no) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4931544A (en) 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
IL80005A (en) 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5512544A (en) 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5153265A (en) 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
GB8806339D0 (en) 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
US5214131A (en) 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5811261A (en) 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE3913101A1 (de) 1989-04-21 1990-10-31 Boehringer Ingelheim Int Tnf-(alpha) bindende proteine und dafuer kodierende dnas
DE59010941D1 (de) * 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
JPH03164179A (ja) * 1989-04-21 1991-07-16 Boehringer Ingelheim Internatl Gmbh Ｔｎｆレセプター、ｔｎｆ結合たん白質およびこれらをコードするｄｎａ
DE3920282A1 (de) 1989-06-21 1991-01-03 Boehringer Ingelheim Int Tnf-rezeptor, tnf bindende proteine und dafuer kodierende dnas
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
DE69017753T3 (de) * 1989-05-18 2013-06-20 Yeda Research And Development Co., Ltd. Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
AU630497B2 (en) 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
EP1132471A3 (de) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
JPH0578396A (ja) 1989-12-13 1993-03-30 Yeda Res & Dev Co Ltd ヒト腫瘍壊死因子結合蛋白
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
AU657483B2 (en) 1990-07-20 1995-03-16 Pharmacia Ab Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2864434B2 (ja) 1991-01-18 1999-03-03 サイナーゲン，インコーポレーテッド 腫瘍壊死因子媒介疾患の治療方法
JPH06508985A (ja) 1991-02-27 1994-10-13 クリエイティブ　バイオモレキュルズ　インコーポレイテッド 富セリンペプチドリンカー
GEP20033082B (en) * 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
WO1994006476A1 (en) 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications

Also Published As

Publication number Publication date
TW206234B (no) 1993-05-21
NZ234499A (en) 1992-08-26
FI903591A0 (fi) 1990-07-16
IL95031A (en) 2007-03-08
AU647397B2 (en) 1994-03-24
PL168844B1 (pl) 1996-04-30
IL131281A0 (en) 2001-01-28
HK1014539A1 (en) 1999-09-30
PT94754B (pt) 1997-04-30
NO306728B3 (no) 2003-02-17
PT94754A (pt) 1991-03-20
KR100230156B1 (ko) 1999-11-15
NO903192L (no) 1991-01-21
JPH03163099A (ja) 1991-07-15
EP0790306A2 (en) 1997-08-20
PL286089A1 (en) 1991-07-29
DE69031997D1 (de) 1998-03-05
AU5897690A (en) 1991-01-24
IE990595A1 (en) 2000-11-15
ATE162801T1 (de) 1998-02-15
GR3026416T3 (en) 1998-06-30
US6541620B1 (en) 2003-04-01
DK0422339T3 (da) 1998-09-23
EP0422339B1 (en) 1998-01-28
SG55131A1 (en) 1998-12-21
IE902608A1 (en) 1991-02-27
KR910015309A (ko) 1991-09-30
NO903192D0 (no) 1990-07-17
FI114398B (fi) 2004-10-15
DE69031997T2 (de) 1998-05-14
CA2021369A1 (en) 1991-01-19
EP0422339A1 (en) 1991-04-17
EP0790306A3 (en) 1998-07-01
IL95031A0 (en) 1991-06-10
ES2116970T3 (es) 1998-08-01

Similar Documents

Publication Publication Date Title
NO306728B1 (no) Fremgangsmåte for fremstilling av en human rekombinant TNF inhibitor og nukleinsyre
AU590896B2 (en) Improved formulations for recombinant beta-interferon
IL90423A (en) Interleukin-1 inhibitors methods for producing them pharmaceutical compositions containing them isolated DNA sequences encoding interleukin-1 inhibitors and host cells and vectors containing them
AU2928789A (en) Low ph pharmaceutical compositions of recombinant beta-interferon
IT8547835A1 (it) Procedimento di purificazione di proteine ossee
JPS6429362A (en) 3-demethylmevalonic acid derivative
HU9501288D0 (en) Recombinant method and host for manufacture of xylitol
WO1997046686A3 (en) Tumor necrosis factor-related polypeptide
AU8920191A (en) Methods and compositions for minimizing inhibition of nucleic acid amplification
Song Synthesis of fluorinated and phosphono diaminopimelic acid (DAP) isomers as inhibitors of DAP enzymes

Legal Events

Date Code Title Description
LC4 Limitation of patent rights - b3 (par. 39b patent act)

Effective date: 20021009

MK1K Patent expired